Infant RSV protection program
Beyfortus (monoclonal antibody) Eligibility
-
Born in 2024 prior to the RSV season
-
Born during the 2024/25 RSV season
-
Children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season, as they meet the Medical Criteria for Increased Risk as listed below
-
Beyfortus should still be administered to the following infants whose gestational parent received Abrysvo:
-
Infants who are born less than 2 weeks after administration of Abrysvo.
-
Infants who meet the Medical Criteria for Increased Risk from severe RSV disease:
-
Chronic lung disease (CLD), including bronchopulmonary dysplasia, requiring ongoing assisted ventilation, oxygen therapy or chronic medical therapy in the six months prior to the start of RSV season
-
Hemodynamically significant congenital heart disease (CHD) requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension
-
Severe immunodeficiency
-
Down syndrome/Trisomy 21
-
Cystic fibrosis with respiratory involvement and/or growth delay
-
Neuromuscular disease impairing clearing of respiratory secretions
-
Severe congenital airway anomalies impairing the clearing of respiratory secretions
Current products available
-
50mg Beyfortus
-
Infants currently under 11 pounds (5 kg) - Beyfortus (Nirsevimab) is available for all babies born in 2024, and 2025 (during RSV season – most likely till April 2025).
-
Infants < 5kg are to receive one dose of 50 mg Beyfortus in 0.5 mL (100 mg/mL)
-
Since early November, hospitals have had 50 mg doses to provide to any newborns prior to discharge.
-
100mg Beyfortus
-
Infants currently equal or over 11 pounds ( ≥ 5kg) - Beyfortus (Nirsevimab) is available for all babies born in 2024, and 2025 (during RSV season).
-
Infants ≥ 5kg are to receive one dose of 100 mg Beyfortus in 1 mL (100 mg/mL)
-
Since late October, hospitals have had 100 mg doses to provide any newborns ≥ 5kg or eligible pediatric patients prior to discharge.
-
200mg Beyfortus HR
-
High Risk infants entering their second RSV season are eligible for a dose of 200mg (2 x 100 mg injections). See above for high-risk infant criteria.
Please see additional information on dosing below in the Beyfortus Dosing Appendix.
Abrysvo (bivalent, subunit vaccine) Eligibility
-
For those in pregnancy (32-36 weeks gestation)
-
Available for pregnant individuals to protect newborns from RSV from birth until they are six months old.
-
Multi-year protection, do not need to repeat if vaccinated last year
-
The infant product Beyfortus is the recommended approach for protection of infants per the National Advisory Committee on Immunization (NACI), with the vaccine in pregnancy being available on a case-by-case basis.
High-risk older adult RSV vaccine program
Abrysvo (bivalent, subunit vaccine) Eligibility
-
Abrysvo, for age 60+ in Long Term Care Homes / Retirement Homes, ALC patients in hospital and select high risk groups (indigenous / underhoused / transplant / dialysis).
-
Multi-year protection, do not need to repeat if vaccinated last year
Arexvy (recombinant, adjuvanted vaccine) Eligibility
-
For age 60+ in Long Term Care Homes / Retirement Homes, ALC patients in hospital and select high risk groups (indigenous /underhoused/transplant/dialysis).
-
Multi-year protection, do not need to repeat if vaccinated last year